Subscribe to Newsletter
Manufacture Advanced Medicine

Advanced Medicine in Brief

  • Bayer is paying $2 billion upfront and up to $2 billion in success-based milestone payments to acquire gene therapy developer AskBio. AskBio has a pipeline of gene therapies, including programs for Parkinson's, congestive heart failure, and Pompe disease in early human trials. “Instead of going to Wall Street and every quarter trying to make milestones, we have one financial partner with which we're trying to bring this technology to fruition,” said Sheila Mikhail, AskBio CEO (1).
  • Losing muscle mass is a significant problem for older people and is partly due to a loss of the regenerative functions of satellite cells. Now, a team of researchers mainly based in Spain have found a subgroup of satellite cells that, due to FoxO activation, maintain their regenerative capacity over time, declining only at geriatric age. The scientists hope that their findings will help “harness the potential of stem cells for regenerative medicine in sarcopenia (2).”
  • Techniques to culture and control cells have improved a lot over the years, but finding the perfect conditions to keep undifferentiated cells alive and prevent them from acquiring a different cellular state remains tricky. Now, researchers in Singapore and Australia have developed a computational biology algorithm called EpiMogrify, which predicts factors that maintain cell state in vitro and identifies factors that induce cell conversion. The team reported a significant increase in the efficiency of astrocyte and cardiomyocyte differentiation using EpiMogrify-predicted factors for conversion conditions. (3)

Want to stay up to date with all the advanced medicine news each week? Subscribe – for free – to The Cell + Gene Curator:

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Bayer, “Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy” (2020). Available at: 
  2. L Garcia-Prat et al., “FoxO maintains a genuine muscle stem-cell quiescent state until geriatric age” Nat Cell Bio (2020). 
  3. US Kamaraj et al., “EpiMogrify Models H3K4me3 Data to Identify Signaling Molecules that Improve Cell Fate Control and Maintenance” Cell Syst (2020).
About the Author
James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.


From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine